id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2020-D-1136-0085,FDA,FDA-2020-D-1136,Development of Monoclonal Antibody Products Targeting SARS-CoV-2 for Emergency Use Authorization,Other,Guidance,2023-12-22T05:00:00Z,2023,12,2023-12-22T05:00:00Z,,2024-11-12T06:25:32Z,,1,0,090000648634e5c5
FDA-2020-D-1136-0084,FDA,FDA-2020-D-1136,"Development of Monoclonal Antibody Products Targeting SARS–CoV–2 for
Emergency Use Authorization; Guidance for Industry; Availability",Notice,Notice of Availability,2023-12-21T05:00:00Z,2023,12,,,2023-12-21T16:06:18Z,2023-28092,0,0,090000648634e184
FDA-2020-D-1136-0083,FDA,FDA-2020-D-1136,"Food and Drug Administration; Center of Drug Evaluation and Research Guidance Documents Related to
Coronavirus Disease 2019, Expiration",Notice,Withdrawal,2023-10-19T04:00:00Z,2023,10,2023-10-19T04:00:00Z,,2023-10-19T13:20:17Z,2023-23071,0,0,090000648610bf60
FDA-2020-D-1136-0082,FDA,FDA-2020-D-1136,Guidance Documents Related to Coronavirus Disease 2019 (COVID–19),Notice,General Notice,2023-03-13T04:00:00Z,2023,3,2023-03-13T04:00:00Z,,2023-03-13T14:28:59Z,2023-05094,0,0,090000648579bdb9
FDA-2020-D-1136-0081,FDA,FDA-2020-D-1136,Temporary Policy on Repackaging or Combining Propofol Drug Products During the COVID–19 Public Health Emergency; Withdrawal of Guidance,Notice,Withdrawal,2023-02-10T05:00:00Z,2023,2,2023-02-10T05:00:00Z,,2023-02-10T15:41:04Z,2023-02809,0,0,0900006485653eb7